Literature DB >> 14768062

Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.

Nicolle H R Litjens1, Mirjam Rademaker, Bep Ravensbergen, Delphine Rea, Mariena J A van der Plas, Bing Thio, Andrew Walding, Jaap T van Dissel, Peter H Nibbering.   

Abstract

Psoriasis vulgaris, a type-1 cytokine-mediated chronic skin disease, can be treated successfully with fumaric acid esters (FAE). Beneficial effects of this medication coincided with decreased production of IFN-gamma. Since dendritic cells (DC) regulate the differentiation of T helper (Th) cells, this study focussed on effects of monomethylfumarate (MMF, bioactive metabolite of FAE) on polarization of monocyte-derived DC. MMF-incubated, lipo-polysaccharide-stimulated DC (MMF-DC) produced dramatically (p<0.05) reduced levels of IL-12p70 and IL-10 (8+/-4% and 20+/-4%, respectively) compared to control DC. MMF-DC were mature. MMF affected polarization of DC irrespective of polarization factor(s) and ligands for the various Toll-like receptors used. Coculture of MMF-DC with naive and primed allogenous Th cells resulted in lymphocytes producing less IFN-gamma, i.e. 59% and 54% of that by the respective Th cells cocultured with control DC. IL-4 production by primed, but not naive Th cells cocultured with MMF-DC was decreased as compared to cocultures with control DC. IL-10 production by naive and primed Th cells cocultured with MMF-DC and control DC did not differ. In addition, MMF inhibited LPS-induced NF-kappaB activation in DC. Together, beneficial effects of FAE in psoriasis involve modulation of DC polarization by MMF such that these cells down-regulate IFN-gamma production by Th cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14768062     DOI: 10.1002/eji.200324174

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  34 in total

Review 1.  Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Authors:  Ralf A Linker; Aiden Haghikia
Journal:  Ther Adv Chronic Dis       Date:  2016-06-10       Impact factor: 5.091

2.  Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.

Authors:  S Schilling; S Goelz; R Linker; F Luehder; R Gold
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 3.  Angiogenesis drives psoriasis pathogenesis.

Authors:  Regina Heidenreich; Martin Röcken; Kamran Ghoreschi
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

4.  Ulcerated necrobiosis lipoidica as a rare cause for chronic leg ulcers: case report series of ten patients.

Authors:  Cindy Franklin; Maren Stoffels-Weindorf; Uwe Hillen; Joachim Dissemond
Journal:  Int Wound J       Date:  2013-10-07       Impact factor: 3.315

Review 5.  Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.

Authors:  Roberto Bomprezzi
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

Review 6.  Toll-Like Receptor Pathways in Autoimmune Diseases.

Authors:  Ji-Qing Chen; Peter Szodoray; Margit Zeher
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

7.  Anti-Psoriatic Drug Monomethylfumarate Increases Nuclear Factor Erythroid 2-Related Factor 2 Levels and Induces Aquaporin-3 mRNA and Protein Expression.

Authors:  Inas Helwa; Vivek Choudhary; Xunsheng Chen; Ismail Kaddour-Djebbar; Wendy B Bollag
Journal:  J Pharmacol Exp Ther       Date:  2017-05-17       Impact factor: 4.030

Review 8.  Psoriasis: advances in pathophysiology and management.

Authors:  A MacDonald; A D Burden
Journal:  Postgrad Med J       Date:  2007-11       Impact factor: 2.401

9.  Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

Authors:  D Moharregh-Khiabani; R A Linker; R Gold; M Stangel
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Toll-like receptors: role in dermatological disease.

Authors:  Aswin Hari; Tracy L Flach; Yan Shi; P Régine Mydlarski
Journal:  Mediators Inflamm       Date:  2010-08-22       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.